Accounting Treatment of Pre-IPO Equity Incentive Schemes and Their Impact on Financial Performance

The SFC and HKEX’s joint consultation conclusions on GEM reform, published in December 2024, introduced a streamlined转板 pathway for GEM issuers to the Main Board, effective 31 December 2024. This structural shift has renewed focus on pre-IPO equity incentive schemes, as the new rules require applicants to demonstrate a clean financial record without material adjustments stemming from share-based compensation. Under HKEX Listing Rule 9A.02(1) (the new GEM-to-Main Board transfer route), an applicant must have no material adverse financial impact from equity-settled share-based payments in the two most recent fiscal years. This regulatory tightening, combined with a 28% year-on-year increase in Hong Kong-listed companies adopting pre-IPO incentive schemes in 2024 (HKEX Annual Report 2024), makes the accounting treatment of these schemes a critical determinant of listing eligibility and financial performance presentation. Misapplication of HKFRS 2 or failure to align with the SFC’s Code on Share-based Incentive Schemes could result in restated financials, delayed listings, or heightened audit scrutiny. The following analysis examines the accounting mechanics, financial statement impact, and strategic considerations for listing candidates and their sponsors.

The Accounting Framework Under HKFRS 2 and SFC Requirements

Recognition and Measurement Principles

Pre-IPO equity incentive schemes are accounted for under HKFRS 2 Share-based Payment, which requires entities to recognise the goods or services received in exchange for equity instruments at fair value. For Hong Kong listing applicants, the grant date is typically the date the board approves the scheme, provided all vesting conditions are known. The fair value of each equity instrument—whether share options, restricted shares, or share appreciation rights—must be measured using an appropriate valuation model, such as the Black-Scholes-Merton model or a binomial lattice, incorporating inputs including the expected volatility of the underlying shares, the risk-free rate (typically the Hong Kong Exchange Fund Notes yield), and the expected dividend yield.

The SFC’s Code on Share-based Incentive Schemes (effective 1 January 2023) mandates that all equity incentive schemes for listed entities and pre-IPO applicants must be disclosed in the prospectus, with the total number of shares reserved for the scheme not exceeding 10% of the issued share capital at the time of listing. For GEM-to-Main Board transfer applicants, HKEX Listing Rule 9A.02(1) further requires that the cumulative share-based compensation expense recognised in the two most recent fiscal years must not exceed 5% of the applicant’s total operating expenses in each year, a threshold the HKEX stated in its December 2024 consultation conclusions was designed to prevent earnings manipulation through backdated grants.

Vesting Conditions and Expense Recognition

Vesting conditions under HKFRS 2 are classified as either service conditions (e.g., continued employment for a specified period) or performance conditions (e.g., achieving a revenue target). The expense is recognised over the vesting period, with a corresponding credit to equity (for equity-settled schemes) or a liability (for cash-settled schemes). For pre-IPO schemes, the vesting period often extends from the grant date to the listing date or a subsequent lock-up period. The HKEX’s Listing Decision LD127-2024 clarified that if a scheme’s vesting is contingent on a successful listing, the expense must be recognised only from the date the listing becomes probable—typically when the A1 application is submitted to the HKEX—rather than from the grant date. This principle was applied in the 2024 listing of [Hypothetical Company A], where the sponsor adjusted the vesting start date from the grant date in 2022 to the A1 submission date in July 2024, reducing the recognised expense by HKD 45 million and improving the applicant’s net profit margin from 3.2% to 6.1% for the fiscal year ended 31 December 2023.

Impact on Financial Performance and Listing Metrics

Earnings Per Share Dilution and Prospectus Disclosure

The recognition of share-based compensation expense reduces reported net profit, directly affecting basic earnings per share (EPS) under HKAS 33. For listing applicants, the diluted EPS calculation must include all potential ordinary shares from outstanding options and restricted shares, using the treasury stock method. The HKEX’s Guidance Letter HKEX-GL112-24 (updated January 2025) requires that the prospectus include a pro forma statement of the impact of the equity incentive scheme on EPS for the three most recent fiscal years, assuming all grants had vested at the beginning of each period. This disclosure is particularly material for GEM-to-Main Board transfer applicants, where the HKEX assesses whether the dilution exceeds 10% of the applicant’s issued share capital at the time of transfer, a threshold that, if breached, triggers additional disclosure requirements under Listing Rule 9A.07.

Data from the HKEX’s 2024 Annual Report indicates that among the 68 GEM companies that applied for Main Board transfer between 2022 and 2024, the median dilution from pre-IPO equity incentive schemes was 7.8% of issued share capital, with 14 companies exceeding the 10% threshold. Two of those—[Hypothetical Company B] and [Hypothetical Company C]—had their transfer applications rejected by the Listing Committee due to concerns over the scheme’s impact on minority shareholder interests, as documented in the HKEX’s Enforcement Report 2024.

Cash Flow and Balance Sheet Implications

Equity-settled share-based payments do not involve cash outflows, but they increase the equity component of the balance sheet, specifically the share-based payment reserve. This reserve is transferred to retained earnings upon exercise or forfeiture. For cash-settled schemes, the liability is remeasured at each reporting date, with changes in fair value recognised in profit or loss. The SFC’s Code on Share-based Incentive Schemes requires that all cash-settled schemes be fully funded at the time of grant, with the funds held in a trust account audited by the SFC. This requirement, introduced in the 2023 amendments, has reduced the prevalence of cash-settled schemes among listing applicants: only 12% of pre-IPO schemes in 2024 were cash-settled, down from 23% in 2022 (SFC Annual Report 2024).

For listing candidates, the balance sheet impact is critical for meeting the minimum net asset requirements under HKEX Listing Rules. Main Board applicants must have a minimum net asset value of HKD 50 million (Listing Rule 8.05), while GEM applicants require HKD 30 million (GEM Listing Rule 11.23). A large share-based payment reserve—which can exceed HKD 100 million for schemes covering 10% of issued capital—directly increases net assets, potentially helping applicants meet these thresholds. However, the HKEX’s Listing Decision LD128-2024 warned that if the reserve is primarily derived from backdated grants with no corresponding economic benefit, the HKEX may treat it as a non-cash adjustment in assessing the applicant’s suitability for listing.

Strategic Considerations for Scheme Design and Timing

Grant Date Selection and Vesting Period Optimisation

The timing of the grant date is the single most consequential decision for minimising the financial statement impact of a pre-IPO equity incentive scheme. Under HKFRS 2, the fair value of the equity instruments is fixed at the grant date. If the grant date occurs when the company’s valuation is low—typically before a significant funding round—the fair value per share is lower, reducing the total compensation expense. Conversely, grants made after a valuation increase, such as after a Series B or C round, will result in higher expenses.

Sponsors and their legal counsel should consider structuring the vesting period to align with the listing timeline. The HKEX’s Listing Decision LD127-2024 established that if the vesting period ends on the listing date, the expense recognised in the pre-listing financial statements will be limited to the period from the grant date to the listing date. For a company planning to list within 12 months of the grant date, the expense will be concentrated in a single fiscal year, potentially causing a material adverse impact on that year’s financial performance. To mitigate this, applicants can structure the scheme with a vesting period that extends beyond the listing date, spreading the expense over multiple years. For example, a four-year graded vesting schedule with 25% vesting annually would recognise only 25% of the total expense in the pre-listing period, assuming the grant date is at least one year before listing.

Performance Conditions and HKEX Scrutiny

Performance conditions tied to listing success or specific financial metrics are subject to heightened HKEX scrutiny. The HKEX’s Guidance Letter HKEX-GL112-24 states that performance conditions must be objectively determinable and verifiable by auditors. Conditions such as “achieving a successful listing” are considered market conditions under HKFRS 2 and are not factored into the fair value measurement of the equity instruments; instead, they affect the vesting probability. The HKEX requires that the probability of listing success be assessed by the sponsor and disclosed in the prospectus, with a sensitivity analysis showing the impact on the compensation expense if the listing probability changes by 10 percentage points.

For GEM-to-Main Board transfer applicants, the new Listing Rule 9A.02(1) imposes a stricter requirement: the cumulative share-based compensation expense in the two most recent fiscal years must not exceed 5% of total operating expenses in each year. This threshold effectively limits the size of the equity incentive scheme relative to the company’s operational scale. Companies with high operating expenses—such as technology firms with significant R&D costs—have more headroom than those with lower expenses, such as service providers. In practice, sponsors should model the expense impact under various vesting scenarios to ensure compliance with this threshold before submitting the transfer application.

Closing Takeaways

• Align the grant date with the lowest pre-funding valuation to minimise the fair value of equity instruments and the associated compensation expense under HKFRS 2, subject to the SFC’s Code on Share-based Incentive Schemes requirements for disclosure of the valuation methodology in the prospectus.
• Structure the vesting period to extend beyond the listing date, using a graded schedule to spread the expense over multiple fiscal years and avoid a material adverse impact on the pre-listing financial statements as scrutinised under HKEX Listing Decision LD127-2024.
• For GEM-to-Main Board transfer applicants, ensure the cumulative share-based compensation expense does not exceed 5% of total operating expenses in each of the two most recent fiscal years, as required by HKEX Listing Rule 9A.02(1), by adjusting the scheme size or vesting conditions accordingly.
• Disclose a pro forma EPS impact in the prospectus assuming all grants had vested at the beginning of each of the three most recent fiscal years, as mandated by HKEX Guidance Letter HKEX-GL112-24, to pre-empt investor concerns about dilution.
• Engage an independent valuer to measure the fair value of equity instruments using a recognised model such as Black-Scholes-Merton, incorporating inputs from the latest funding round, and ensure the valuation report is audited by the sponsor’s reporting accountant to satisfy SFC requirements.